Personalis (NASDAQ:PSNL) Releases Earnings Results, Beats Expectations By $0.09 EPS

Personalis (NASDAQ:PSNL) posted its quarterly earnings data on Thursday. The company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($0.32) by $0.09, Zacks reports. The firm had revenue of $16.80 million during the quarter, compared to analyst estimates of $15.48 million. Personalis had a negative return on equity of 66.07% and a negative net margin of 104.52%. Personalis updated its FY 2025 guidance to EPS and its Q1 2025 guidance to EPS.

Personalis Stock Down 2.4 %

Shares of Personalis stock opened at $4.14 on Friday. The company has a market capitalization of $292.48 million, a price-to-earnings ratio of -2.46 and a beta of 1.73. The stock’s 50-day simple moving average is $5.40 and its 200-day simple moving average is $5.04. Personalis has a 52 week low of $1.13 and a 52 week high of $7.20.

Wall Street Analyst Weigh In

A number of brokerages have commented on PSNL. HC Wainwright restated a “buy” rating and issued a $8.00 price target on shares of Personalis in a research report on Friday. Lake Street Capital boosted their price objective on Personalis from $7.00 to $9.00 and gave the company a “buy” rating in a research note on Wednesday, January 8th. Finally, Needham & Company LLC decreased their target price on shares of Personalis from $7.25 to $7.00 and set a “buy” rating on the stock in a research note on Friday.

About Personalis

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.